<DOC>
	<DOCNO>NCT01782664</DOCNO>
	<brief_summary>A multi-centre , randomise , dose range study evaluate safety clinical efficacy GSK2586184 patient chronic plaque psoriasis . There 2 study cohort ( Cohorts A B ) . Cohort A main study cohort , part study randomise , double-blind placebo-controlled . Fifty-six subject randomise Cohort A : 14 subject treatment group : 100 mg , 200 mg 400 mg GSK2586184 , placebo . Cohort B exploratory , open-label investigation effect 400 mg GSK2586184 inflammatory gene expression skin whole blood , GSK2586184 concentration skin . A maximum 8 subject include , subject take 400 mg GSK2586184 . In Cohorts A B , study medication administer orally ( tablet ) , twice daily , 12 week . Each subject 7 out-patient visit : Screening ; Baseline &amp; Start treatment ; Week 2 ; Week 4 ; Week 8 ; Week 12 ; Follow-up ( Week 16 )</brief_summary>
	<brief_title>A Dose Ranging Study Evaluate Safety Efficacy GSK2586184 Patients With Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Otherwise healthy subject diagnosis moderate severe plaque psoriasis define follow criterion : Diagnosed least 12 month first dose study medication Psoriasis plaques cover &gt; =10 % body surface area . PASI score &gt; =12 , PGA score &gt; =3 , suitable systemic light therapy . Male female , 18 75 year age inclusive . Female subject childbearing potential must agree avoid pregnancy male subject must agree avoid female partner become pregnant . Subjects must agree use ultra violet ( UV ) light protection . Capable give write informed consent , include compliance requirement restriction list consent form . Unable refrain use follow prescription nonprescription drug follow period first dose study medication completion followup visit : 12 week : alefacept , ustekinumab , adalimumab , etanercept , infliximab , certolizumab pegol 4 week 5 halflives , whichever longer : systemic medication medical condition know affect psoriasis , include limited oral corticosteroid , cyclosporine , methotrexate , lithium , betaadrenergic blocker 7 day 5 halflives , whichever longer : statin OATP BCRP sensitive substrate ( e.g . rapaglinide ) agent know substrate MATE1 MATE2K , undergoes significant renal secretion ( e.g . cimetidine ) 3 week 5 halflives , whichever longer : agent know strong CYP3A4 inhibitor inducer 2 week : topical therapy know affect psoriasis , include limited corticosteroid , retinoids , vitamin D derivative , tar anthralin Other medication ( include vitamin , herbal dietary supplement ) consider casebycase basis , allow opinion investigator medication interfere study procedure compromise subject safety . Phototherapy within 4 week first dose study medication . A live vaccination within 4 week first dose study medication , live vaccination plan course study ( completion followup visit ) . A major organ transplant ( e.g . heart , lung , kidney , liver ) haematopoietic stem cell/marrow transplant . Significant unstable uncontrolled acute chronic disease unrelated psoriasis ( i.e . cardiovascular include uncontrolled hypertension , hypercholesterolemia , pulmonary , hematologic , gastrointestinal , hepatic , renal , neurological , malignancy infectious disease ) , opinion investigator , could confound result study put subject undue risk . A planned surgical procedure , opinion investigator , make subject unsuitable study . A history malignant neoplasm within last 5 year , except adequately treat cancer skin ( basal squamous cell ) carcinoma situ uterine cervix . Acute chronic infection , follow : Known previous active infection Mycobacterium Tuberculosis Currently suppressive therapy chronic infection ( pneumocystis , cytomegalovirus , herpes simplex virus , herpes zoster atypical mycobacteria ) . Hospitalisation treatment infection within 60 day first dose . Use parenteral ( IV intramuscular ) antibiotic ( antibacterial , antiviral , antifungal , antiparasitic agent ) within 60 day first dose . Unable refrain consumption grapefruit grapefruit juice 3 week first dose study medication 2 week last dose study medication . History sensitivity component study medication , history drug allergy , opinion investigator , contraindicate participation . Serologic evidence Hepatitis B ( HB ) infection base result test HBsAg , antiHBc antibody follow : subject positive HBsAg exclude ; subject positive antiHBc antibody ( regardless antiHBs antibody status ) exclude . Positive test Hepatitis C antibody confirm sample Hepatitis C RIBA immunoblot assay equivalent . Subjects positive Hepatitis C antibody , negative Hepatitis C RIBA immunoblot assay equivalent test perform eligible participate . Subjects positive Hepatitis C antibody positive indeterminate result Hepatitis C RIBA immunoblot assay equivalent test perform eligible participate . A positive test HIV antibody . Pregnant female determine positive serum hCG test screening , positive urine hCG test predose Day 1 . Lactating female . Haemoglobin &lt; 11 g/dL , haematocrit &lt; 30 % , WBC count ( absolute ) &lt; 3 × 10^9/L , neutrophil &lt; 1.5 × 10^9/L , platelet &lt; 100 × 10^9/L , lymphocytes &lt; 1 x 10^9/L . Current history renal disease , estimate creatinine clearance &lt; 60 mL/min/1.73m^2 serum creatinine &gt; 1.5 ULN . Single QTc &gt; 450 msec ; QTc &gt; 480 msec subject Bundle Branch Block . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . ALT &gt; 2xULN ; alkaline phosphatase bilirubin ≥ 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . History regular alcohol consumption within 6 month study define average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol : halfpint ( ~240 ml ) beer , 1 glass ( 125 ml ) wine 1 ( 25 ml ) measure spirit . The subject participate clinical trial receive investigational product within 3 month first dose study medication , plan take part another clinical trial time participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>PASI</keyword>
	<keyword>DLQI</keyword>
	<keyword>GSK2586184</keyword>
	<keyword>plaque-type psoriasis</keyword>
	<keyword>PGA</keyword>
	<keyword>inflammatory gene transcription</keyword>
	<keyword>JAK-1 inhibitor</keyword>
	<keyword>serum neopterin</keyword>
	<keyword>skin biopsy</keyword>
	<keyword>ACR response criterion</keyword>
	<keyword>VAS itch score</keyword>
</DOC>